Skip to content

Study · Ex vivo tissue · mouse · 1990

4 results

Melanotropin receptors of murine melanoma characterized in cultured cells and demonstrated in experimental tumors in situ.

Tatro JB, Entwistle ML, Lester BR, Reichlin S

Cancer research1 Feb 1990Cited by 31 (Europe PMC)

PMID2153454 (opens in a new tab)PepBankPUB-02153454
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In sections of mouse B16-F10C23 tumors, specific 125I-NDP-MSH binding sites were present throughout the tumor tissue but not in fibrovascular elements or neighboring non-melanoma tissue.

    In plain wordsIn lab tests on mouse melanoma tumor sections, NDP-MSH bound inside the tumor tissue but not in the surrounding tissue.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableDistribution of NDP-MSH binding sites in mouse melanoma tumors
    Study

    mousen: not reported in source

    frozen sections of B16-F10C23 tumors
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tumors were induced by inoculation of C57BL/6 mice with B16-F10C23 cells, and the presence of 125I-NDP-MSH binding sites was determined by in situ radiolabeling of frozen tissue sections followed by autoradiography.
    2 context sentences
    Summary · context
    Specific MSH binding sites were distributed throughout the tumor tissue, but not in associated fibrovascular elements or in neighboring nonmelanoma tissues.
    Summary · context
    The binding properties of MSH receptors in intact cells of a highly metastatic, highly MSH-responsive mouse melanoma cell subline (B16-F10C23) were determined using a radiolabeled, biologically active preparation of the superpotent alpha-MSH analogue, [Nle4,D-Phe7]-alpha-MSH (125I-NDP-MSH).
  2. 02LabIn vitro (cells)Activity measurement

    In mouse melanoma B16-F10C23 cells, NDP-MSH bound to a single high-affinity class of binding site with a Kd of 5.6 x 10(-11) M.

    In plain wordsIn mouse melanoma cells, NDP-MSH bound very tightly to a single class of binding site.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableNDP-MSH binding affinity (Kd) in B16-F10C23 cells
    Study

    mousen: not reported in source

    B16-F10C23 mouse melanoma cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Measurements

    Kd
    5.6 x 10(-11) M
    B16-F10C23 cells, Scatchard analysis

    Source sentences

    Summary
    A single high-affinity class of binding site was detected (Kd for NDP-MSH, 5.6 x 10(-11) M; Kd for alpha-MSH, 2.6 x 10(-9) M as determined by Scatchard analysis and heterologous inhibition assays, respectively)
    1 context sentence
    Summary · context
    The binding properties of MSH receptors in intact cells of a highly metastatic, highly MSH-responsive mouse melanoma cell subline (B16-F10C23) were determined using a radiolabeled, biologically active preparation of the superpotent alpha-MSH analogue, [Nle4,D-Phe7]-alpha-MSH (125I-NDP-MSH).
  3. 03LabIn vitro (cells)Activity measurement

    In mouse melanoma cells, the potencies of NDP-MSH, alpha-MSH and ACTH in binding and biological assays were highly correlated.

    In plain wordsIn mouse melanoma cells, how strongly NDP-MSH bound matched how strongly it acted in the cell assay.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableCorrelation of binding and biological potency
    Study

    mousen: not reported in source

    B16-F10C23 mouse melanoma cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, the respective potencies of three melanotropins, NDP-MSH, alpha-MSH, and adrenocorticotropic hormone, in binding and biological assays were highly correlated.
    2 context sentences
    Summary · context
    These results indicate that the 125I-NDP-MSH binding site represents the functional MSH receptor.
    Summary · context
    The binding properties of MSH receptors in intact cells of a highly metastatic, highly MSH-responsive mouse melanoma cell subline (B16-F10C23) were determined using a radiolabeled, biologically active preparation of the superpotent alpha-MSH analogue, [Nle4,D-Phe7]-alpha-MSH (125I-NDP-MSH).

Studies that did not test the peptide alone1

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 04LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueActivity measurement

    In mouse melanoma tumor sections, melanotropins inhibited 125I-NDP-MSH binding in a concentration-dependent manner.

    In plain wordsIn lab tests on mouse tumor sections, other melanotropins blocked the binding of labelled NDP-MSH in a dose-related way.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseMelanotropin inhibition of 125I-NDP-MSH binding in tumor sections
    Study

    mousen: not reported in source

    frozen sections of B16-F10C23 tumors
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    As in cultured B16-F10C23 cells, melanotropins inhibited 125I-NDP-MSH binding to tissue sections in a concentration-dependent manner.
    1 context sentence
    Summary · context
    The binding properties of MSH receptors in intact cells of a highly metastatic, highly MSH-responsive mouse melanoma cell subline (B16-F10C23) were determined using a radiolabeled, biologically active preparation of the superpotent alpha-MSH analogue, [Nle4,D-Phe7]-alpha-MSH (125I-NDP-MSH).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.